5 min read

Sfunga Therapeutics and Deerfield Management Announce Publication on Novel Antifungal SF001 in Nature

– SF001, with QIDP and FDA Fast Track designations, in Phase 1 clinical development –

Written by

Published on

Updated on

November 8, 2023

Share this post